Bio-effect model applied to 131I radioimmunotherapy of refractory non-Hodgkin's lymphoma.
about
Relational grounding facilitates development of scientifically useful multiscale modelsTumor-Absorbed Dose Predicts Progression-Free Survival Following (131)I-Tositumomab RadioimmunotherapyBiological-effect modeling of radioimmunotherapy for non-hodgkins lymphoma: determination of model parameters.The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy.Beyond Dose: Using Pretherapy Biomarkers to Improve Dose Prediction of Outcomes for Radioimmunotherapy of Non-Hodgkin Lymphoma.Combination of liquid scintillation counting and passive sampling strategy for the determination of131I in air and application to estimate the inhalation dose to the staff of a nuclear medicine service
P2860
Bio-effect model applied to 131I radioimmunotherapy of refractory non-Hodgkin's lymphoma.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Bio-effect model applied to 131I radioimmunotherapy of refractory non-Hodgkin's lymphoma.
@ast
Bio-effect model applied to 131I radioimmunotherapy of refractory non-Hodgkin's lymphoma.
@en
type
label
Bio-effect model applied to 131I radioimmunotherapy of refractory non-Hodgkin's lymphoma.
@ast
Bio-effect model applied to 131I radioimmunotherapy of refractory non-Hodgkin's lymphoma.
@en
prefLabel
Bio-effect model applied to 131I radioimmunotherapy of refractory non-Hodgkin's lymphoma.
@ast
Bio-effect model applied to 131I radioimmunotherapy of refractory non-Hodgkin's lymphoma.
@en
P2093
P2860
P1476
Bio-effect model applied to 131I radioimmunotherapy of refractory non-Hodgkin's lymphoma.
@en
P2093
Anca M Avram
Hanan Amro
Mark S Kaminski
Matthew J Schipper
Peter L Roberson
Scott J Wilderman
Yuni K Dewaraja
P2860
P2888
P304
P356
10.1007/S00259-010-1699-3
P577
2010-12-21T00:00:00Z